Salbutamol Oral Liquid Global Market Report 2025

The salbutamol oral liquid market size has grown strongly in recent years. It will grow from $1.11 billion in 2024 to $1.17 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The expansion during the historical period was driven by factors such as a rising number of asthma cases, increased public awareness of chronic respiratory illnesses, a growing elderly population, heightened demand for pediatric respiratory therapies, and escalating air pollution levels causing respiratory health issues.

The salbutamol oral liquid market size is expected to see strong growth in the next few years. It will grow to $1.45 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. Factors contributing to this projected growth include broader acceptance of online pharmacy platforms, heightened public education on asthma control, increased healthcare expenditures, a higher frequency of allergic respiratory conditions, and an increased inclination towards liquid dosage forms. Key trends expected during this period involve the development of innovative formulations, integration of digital tracking in packaging, customized dosing technologies, cloud-integrated supply networks, and eco-friendly packaging solutions.

The increasing incidences of respiratory disorders are expected to drive the growth of the salbutamol oral liquid market in the coming years. Respiratory disorders, which affect the lungs and airways, hinder breathing and the body’s ability to exchange oxygen. A rise in these disorders is largely attributed to growing air pollution and exposure to environmental pollutants. Salbutamol oral liquid is commonly used in the treatment of respiratory disorders to relax airway muscles, ease bronchospasms, and improve airflow, helping to relieve symptoms such as wheezing, shortness of breath, and chest tightness. For example, in November 2023, the National Asthma Council Australia reported that Australia experienced 467 asthma-related deaths in 2022 - 299 females and 168 males - up from 355 deaths in 2021. As a result, the growing number of respiratory disorders is boosting the demand for salbutamol oral liquid.

The increase in healthcare expenditures is anticipated to support the expansion of the salbutamol oral liquid market. Healthcare expenditures encompass the total spending on medical services and products, such as hospital care, physician visits, medications, and public health programs. Rising healthcare costs are often linked to the adoption of advanced medical treatments and technologies. Higher healthcare spending can benefit the salbutamol oral liquid market by enhancing access to essential respiratory medications, facilitating the diagnosis and treatment of conditions like asthma and COPD, and enabling broader distribution of bronchodilators, particularly in under-resourced regions. For instance, in May 2024, the UK’s Office for National Statistics reported a 5.6% nominal increase in total healthcare expenditure from 2022 to 2023, a significant rise compared to the 0.9% growth in 2022. This trend in rising healthcare investments is thus contributing to the growth of the salbutamol oral liquid market.

The increase in air pollution is projected to further fuel the salbutamol oral liquid market’s growth. Air pollution involves the presence of harmful airborne substances that pose risks to human health, ecosystems, and the climate. This pollution is increasingly driven by emissions from industrial processes and fossil fuel combustion. Salbutamol oral liquid helps mitigate breathing difficulties caused by air pollution by relaxing airway muscles and improving airflow to the lungs. For instance, in October 2023, the UK Office for National Statistics noted a 2% year-over-year increase in greenhouse gas emissions on a residence basis from 2021 to 2022. Consequently, the growing levels of air pollution are contributing to the rising demand for salbutamol oral liquid.

Major players in the salbutamol oral liquid market are GlaxoSmithKline plc, Cipla Limited, Lupin Limited, Amphastar Pharmaceuticals Inc., Beximco Pharmaceuticals Limited, Beta Healthcare International Limited, Sakar Healthcare Limited, Pharmatec Pakistan (Private) Limited, Infinity Pharma, Azaria Pharmaceutical Laboratories Inc., Salvavidas Pharmaceutical Private Limited, Lucky Pharmaceuticals, Wellona Pharma, Centurion Healthcare Private Limited, Niksan Pharmaceutical, SUNWARD PHARMACEUTICAL SDN. BHD., Glumex Pharmaceuticals Mfg. Pvt. Ltd., Indo Rama Engineers, Elikem Pharmaceuticals Private Limited, and CCI Products.

North America was the largest region in the salbutamol oral liquid market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in salbutamol oral liquid report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the salbutamol oral liquid market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Salbutamol oral liquid refers to a medication formulation containing salbutamol, a bronchodilator that helps relax the muscles in the airways. It is used for the relief and prevention of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD).

The primary types of salbutamol oral liquid include oral liquid solutions and oral liquid suspensions. Oral liquid solutions of salbutamol are bronchodilator drugs in liquid form, commonly utilized to alleviate symptoms of asthma, bronchitis, and other obstructive respiratory conditions by relaxing airway muscles and enhancing airflow to the lungs. These formulations come in various forms such as syrup, solution, and concentrate, and contain active components like albuterol, levalbuterol, pirbuterol, salmeterol, and formoterol. The distribution of salbutamol oral liquids takes place through multiple channels including hospital pharmacies, retail pharmacies, and online pharmacies, and they are used to treat asthma, COPD, and various other respiratory ailments.

The salbutamol oral liquid market research report is one of a series of new reports that provides salbutamol oral liquid market statistics, including the salbutamol oral liquid industry global market size, regional shares, competitors with the salbutamol oral liquid market share, detailed salbutamol oral liquid market segments, market trends, and opportunities, and any further data you may need to thrive in the salbutamol oral liquid industry. This salbutamol oral liquid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The salbutamol oral liquid market consists of sales of ventolin syrup, asthalin syrup, salbetol syrup, bronkotab syrup, salbulin syrup, ventair syrup. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.